M201-A
Drug for heart failure, atrial fibrillation and kidney disease
A novel therapeutic agent for heart failure, atrial fibrillation and chronic kidney disease, ryanodine receptor 2 inhibitor, M201-A
2023/11
Phase II clinical trials of M201-A injection for patients with heart failure and renal dysfunction were initiated in the first semester.
2021/01
A Phase I repeated-dose study of M201-A injection was completed. We confirmed the effects of M201-A on Na diuresis and improvement of renal function in humans with mild renal dysfunction.
2020/03
A dose-escalation, placebo-controlled, double-blind, randomised Phase I repeated-dose study of M201-A hydrochloride injection in healthy adults was initiated.
We are an academia-initiated bio-venture aiming to develop drugs for unmet medical needs.We are researching and developing novel therapeutic agents for heart and kidney diseases, both of which are increasing in terms of the number of patients in an ageing society.The Company is developing ryanodine receptor 2 inhibitors, K201 and M201-A.